Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Luke's Episcopal Health System

www.stlukestexas.com

Latest From Abbott Bioresearch Center

Leveraging Antibodies

Human antibodies are hot. Three leading companies with patented means for making them are battling for partners and strategic position, anxious to sign alliances before current competitors muscle in, or next-generation technologies come along. Abgenix and Medarex effectively share a duopoly on transgenic mice that make human antibodies. Both firms license their technologies on an antigen-by-antigen basis, but are moving to build more value by deploying the methods on their own behalf, and via 50/50 deals with companies willing to share targets and development costs. Cambridge Antibody Technology is the leading promoter of phage-display technology, a bacterially-based, relatively high throughput method of making human antibody fragments that can be used as reagents to validate targets, or built up into drugs. Owning products is the end-game for all three players. But their approaches to the goal differ, particularly in the way they're structuring deals and the number of products they intend to put into clinical development.
BioPharmaceutical Strategy

Chemical Conversions

Interviews with the heads of R&D at a mid-sized drug firm (Ulrich Grau, BSAF Pharma) and a very large one (Wolfgang Hartwig, Bayer AG), both based in Germany, in which they discuss how their companies' research strategies are evolving in response to industry consolidation. Some Industry observers argue that pharmaceutical M&A has created entities of such massive scale that mid-sized organizations will soon be unable to compete. But Ulrich Grau argues that huge size is not an advantage in R&D because scientists tend to do their best work in small groups. He adds that BASF intends to leverage the flexibility its size enables to become more responsive to in-house research findings and to biotech partners it will seek out for the first time. Bayer thinks it can be more flexible than the industry's giants. To balance its chemical bent, Bayer has recently spent large sums to ally with partners whose technologies support work in 15 research areas.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Services
  • Therapeutic Areas
  • Alias(es)
  • St. Luke's Health System
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Tech. Transfer Entity
  • Parent & Subsidiaries
  • St. Luke's Episcopal Health System
  • Senior Management
  • Michael K Jhin, Pres. & CEO
    Alan F Koval, EVP, CFO
  • Contact Info
  • St. Luke's Episcopal Health System
    Phone: (713) 791-1000
    6720 Bertner Ave.
    Houston, TX 77030
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register